TY - JOUR

T1 - 2019 update to

T2 - Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

AU - Buse, John B.

AU - Wexler, Deborah J.

AU - Tsapas, Apostolos

AU - Rossing, Peter

AU - Mingrone, Geltrude

AU - Mathieu, Chantal

AU - D'Alessio, David A.

AU - Davies, Melanie J.

PY - 2020

Y1 - 2020

N2 - The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals witha glucagon-like peptide1 (GLP-1) receptor agonist or sodium-glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can alsobeconsidered in patients with type 2 diabetes without established cardiovascular disease (CVD) but withthe presence of specific indicators of high risk; and 3)SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min-1 [1.73 m]2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.

AB - The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals witha glucagon-like peptide1 (GLP-1) receptor agonist or sodium-glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can alsobeconsidered in patients with type 2 diabetes without established cardiovascular disease (CVD) but withthe presence of specific indicators of high risk; and 3)SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min-1 [1.73 m]2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.

U2 - 10.2337/dci19-0066

DO - 10.2337/dci19-0066

M3 - Journal article

C2 - 31857443

AN - SCOPUS:85078384213

VL - 43

SP - 487

EP - 493

JO - Diabetes Care

JF - Diabetes Care

SN - 0149-5992

IS - 2

ER -